Results 231 to 240 of about 75,755 (323)

Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 16-26, January 2026.
Abstract Chronic kidney disease (CKD) is a serious complication occurring in nearly one of three people with type 1 diabetes (T1D). Major therapeutic advances have been made in the management of CKD for people with type 2 diabetes (T2D), thereby improving their kidney, cardiovascular, and survival outcomes.
Katherine R. Tuttle, Linong Ji, Chantal Mathieu, Jonathan Rosen   +3 more
wiley   +1 more source

Sodium-Glucose Cotransporter 2 Inhibitors-Induced Euglycemic Ketoacidosis Mimicking Myocardial Infarction in a Non-Diabetic Heart Failure Patient. [PDF]

Int J Heart Fail
Pack K, Ha KE, Yang T, Chung WJ.
europepmc   +1 more source

GAS'PING IN SILENCE: DIABETIC KETOACIDOSIS SECONDARY TO BILATERAL EMPHYSEMATOUS PYELONEPHRITIS [PDF]

ALLEN GEORGE, FRANCES OGUNNAYA, Sammir Dekowski, JESSICA MAZUR   +3 more
openalex   +1 more source

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 296-305, January 2026.
Abstract Aims This systematic review and meta‐analysis evaluated the long‐term efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as adjunctive therapies for individuals with type 1 diabetes (T1D) and overweight or obesity. Materials and Methods A literature search was conducted in June 2023 and updated in June 2025.
Amanda R. Purcell, Xi May Zhen, Jencia Wong, Sarah J. Glastras   +3 more
wiley   +1 more source

Low serum 1,5‐anhydroglucitol is associated with increased risk of all‐cause and cardiovascular mortality in type 2 diabetes: A real‐world cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 434-442, January 2026.
Abstract Aims Serum 1,5‐anhydroglucitol (1,5‐AG) indicates glycemic control over 1–2 weeks and is particularly useful for monitoring postprandial hyperglycemia. However, its predictive value for long‐term outcomes in type 2 diabetes has not been fully established.
Jiaying Ni, Lei Chen, Hang Su, Jinghao Cai, Chunfang Wang, Wei Lu, Yufei Wang, Jingyi Lu, Tian Xia, Jian Zhou   +9 more
wiley   +1 more source

Multidisciplinary Management and Anesthesia Considerations for Diabetic Ketoacidosis With Hypertriglyceridemic Acute Pancreatitis in Pregnancy: A Case Report. [PDF]

Am J Case Rep
Liu P, Li T, Yu S, Liu F, Huang L.
europepmc   +1 more source

Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes (iNPHORM, United States)

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 675-690, January 2026.
Abstract Aims Level 3 (severe) hypoglycaemia is a serious, yet preventable, complication of insulin‐ or secretagogue‐treated diabetes. However, real‐world insight into its incidence and risk factors remains limited. We analysed data from the iNPHORM study to address this gap.
Alexandria Ratzki‐Leewing, Jason E. Black, Jasminder Bhatti, Bridget L. Ryan, Guangyong Zou, Yu Kuei Lin, Shuo J. Huang, Rozalina G. McCoy, Stewart B. Harris   +8 more
wiley   +1 more source

Challenges in glycaemic control among women with type 1 diabetes and the role of MiniMed 780G system: A narrative review

Diabetes, Obesity and Metabolism, Volume 28, Issue S1, Page 35-48, January 2026.
Abstract Sex‐based disparities in the incidence, prevalence and disease manifestations have been observed across various medical conditions, including type 1 diabetes (T1D). Differences in glycaemic control and quality of life between men and women have been reported, with women experiencing lower rates of glycaemic targets and a higher risk for long ...
Isabeau Thijs, Sarah E. Siegelaar, Yasmine I. Elhenawy I., Katrien Benhalima, Orit Pinhas‐Hamiel, Tim van den Heuvel, Javier Castañeda, Ohad Cohen   +7 more
wiley   +1 more source

When Falls Reveal Acidosis: Unmasking Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis. [PDF]

Cureus
Kaur J, Dogra A, Haymov A.
europepmc   +1 more source

Association of Deviation From Glycated Hemoglobin (HbA1c) Target in the Guidelines for the Treatment of Diabetes in Older Patients With Place of Care and Interval Between HbA1c Tests Among Older Patients Receiving Home Medical Care

Geriatrics &Gerontology International, Volume 26, Issue 1, January 2026.
ABSTRACT Aim We examined the association of deviation from the glycated hemoglobin (HbA1c) target proposed in the Guidelines for the Treatment of Diabetes in Older Patients in Japan 2016 with the place of care and interval between HbA1c tests among older patients with diabetes.
Mari Fukuhara, Takuma Kimura, Yoshiyuki Sasaki, Satoshi Fukuhara, Suguru Mabuchi, Kazue Ota, Masanaga Yamawaki, Masayoshi Hashimoto   +7 more
wiley   +1 more source